rezafungin
Selected indexed studies
- Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. (Lancet, 2023) [PMID:36442484]
- Rezafungin. (, 2006) [PMID:37247362]
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. (Drugs, 2021) [PMID:34626339]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Echinocandins Pharmacokinetics: A Comprehensive Review of Micafungin, Caspofungin, Anidulafungin, and Rezafungin Population Pharmacokinetic Models and Dose Optimization in Special Populations. (2025) pubmed
- Rezafungin vs caspofungin for the treatment of invasive candidiasis: A systematic review and meta-analysis. (2025) pubmed
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. (2021) pubmed
- Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. (2023) pubmed
- Rezafungin. (2006) pubmed
- Rezafungin: First Approval. (2023) pubmed
- Rezafungin: A Review in Invasive Candidiasis. (2025) pubmed
- Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials. (2024) pubmed
- Rezafungin in special populations with candidaemia and/or invasive candidiasis. (2025) pubmed
- Activity of rezafungin against Candida auris. (2025) pubmed